Sara Pellegrino | Vice President, Investor and Public Relations |
Fred Vogt | Interim President and Chief Executive Officer |
Igor Bilinsky | Chief Operating Officer |
Jim Ziegler | Senior Vice President, Commercial |
Friedrich Finckenstein | Chief Medical Officer |
Jean-Marc Bellemin | Chief Financial Officer |
Tyler Van Buren | Cowen |
Michael Yee | Jefferies |
Peter Lawson | Barclays |
Nick Abbott | Wells Fargo |
Mara Goldstein | Mizuho |
Mark Breidenbach | Oppenheimer |
Colleen Kusy | Baird |
Ben Burnett | Stifel |
Asthika Goonewardene | Truist Securities |
Reni Benjamin | JMP Securities |
Madhu Kumar | Goldman Sachs |
Welcome to the Iovance Biotherapeutics Fourth Quarter and Full Year 2021 Financial Results. My name is Chery, and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded.